[Nonmyeloablative allogeneic peripheral blood stem cell transplantation of renal cell carcinoma].
We presented three cases with refractory metastatic renal cell carcinomas who underwent nonmyeloablative allogeneic peripheral blood stem cell transplantation(PBSCT). A fludarabine and cyclophosphamide-based regimen was used. Complete donor-T-cell chimerism was established at day 94, 40, 52 after PBSCT in each case. GVHD occurred at day 183, 53, 75. In Case 1 and Case 3 apparent GVT effects reduced the metastases at day 212, 261 and let them live longer than expected. Case 2 died at day 69 before GVT effect appeared, because the case was so-called rapid growth type. Histological examinations in Case 1 and Case 3 showed infiltration of lymphocytes disrupting the foci of renal cell carcinomas which was considered as findings of GVT effects.
D000368:Aged; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D020350:Graft vs Tumor Effect; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011379:Prognosis; D018183:Transplantation Chimera; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine